Jubilant Pharmova Limited has announced an earnings webinar scheduled for May 22, 2026, to discuss the financial performance of the company for the financial year 2025-26. The webinar will be conducted from 6:00 pm to 7:00 pm IST, providing investors with insights into the company's operational and financial achievements for the year ended March 31, 2026.

Webinar Details and Schedule

The earnings webinar has been organized under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparent investor communication.

Registration and Participation Guidelines

Pre-registration is mandatory for the webinar, with investors required to register up to 3 hours before the scheduled call. The webinar will commence with a brief management commentary on the financial performance for the financial year ended March 31, 2026, followed by an interactive Q&A session. Participants may join the queue by clicking the "Raise Hand" icon or post questions through chat during the Q&A session.

Regulatory Compliance and Documentation

The presentation made at the webinar will be submitted to the stock exchange before the event and hosted on the company's official website at www.jubilantpharmova.com for broader accessibility. The formal intimation was signed by Naresh Kapoor, Company Secretary, on April 24, 2026, ensuring compliance with disclosure obligations under the Listing Regulations.

Company Background and Operations

Jubilant Pharmova Limited operates as a global pharmaceutical company with diverse business segments including Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Contract Research Development and Manufacturing Organisation (CRDMO), Generics and Proprietary Novel Drugs businesses. The company maintains a network of 45 radiopharmacies in the US and operates multiple manufacturing facilities serving regulated markets including USA, Europe and other geographies, with approximately 5,500 employees worldwide.

Jubilant Pharmova Limited has submitted its quarterly compliance certificate under SEBI regulations for the quarter ended March 31, 2026. The pharmaceutical company filed the mandatory certificate with stock exchanges on April 1, 2026, demonstrating adherence to regulatory requirements for depositories and participants.

Regulatory Compliance Filing

The certificate was filed under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, and submitted to both major Indian stock exchanges. Company Secretary Naresh Kapoor signed and submitted the documentation on behalf of Jubilant Pharmova Limited.

Registrar Confirmation

M/s Alankit Assignments Limited, serving as the company's Registrar and Share Transfer Agent, issued the confirmation certificate. General Manager Kamal Garg signed the certificate on behalf of Alankit Assignments Limited, providing the required regulatory confirmation.

The registrar's certificate confirms two critical compliance aspects:

• Securities comprised in the certificates have been properly listed on stock exchanges
• Physical certificates have been duly verified, mutilated, cancelled, and depository names substituted as registered owners

Depository Notifications

The filing was also copied to both major depositories in India to ensure comprehensive regulatory compliance. The notifications were sent to National Securities Depository Limited at Trade World, Lower Parel, Mumbai, and Central Depository Services (India) Limited at Marathon Futurex, Lower Parel, Mumbai.

Corporate Information

Jubilant Pharmova Limited operates as part of the Jubilant Bhartia Company group, with its registered office located at Bhartiagram, Gajraula, District Amroha, Uttar Pradesh. The company maintains its corporate identification number as L24116UP1978PLC004624, reflecting its incorporation history and regulatory status.